Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Bart Frederick"'
Autor:
Patrick Branigan, Zhenhua Xu, Ivo Nnane, Philipp Badorrek, Damien Fink, Donald Raible, Zhenling Yao, Karen E. Duffy, Maarten van den Boer, Cathye Shu, Bart Frederick, Tong-Yuan Yang, Frédéric Baribaud
Publikováno v:
Br J Clin Pharmacol
Aims To assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of CNTO 7160, an anti-interleukin-33 receptor (IL-33R) monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis (AD). M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56489b453857e0b285608f97a6b7f8fe
https://doi.org/10.1111/bcp.14361
https://doi.org/10.1111/bcp.14361
Autor:
Tatiana Ort, Shannon Dogmanits, Ivo Nnane, Zhenling Yao, Fang Shen, Derrick E. Akpalu, Damien Fink, Donald Raible, Zhenhua Xu, Amarnath Sharma, Bart Frederick
Publikováno v:
Journal of clinical pharmacology. 59(7)
The safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of JNJ-61178104, a novel anti-tumor necrosis factor-alpha (TNFα) and anti-interleukin-17A (IL-17A) bispecific antibody, were investigated in a placebo-controlled, first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d25d6e46347165fe973fad4bdee729ef
https://pubmed.ncbi.nlm.nih.gov/30776134
https://pubmed.ncbi.nlm.nih.gov/30776134
Autor:
Joyce Ford, Bart Frederick, Joseph C. Marini, Manny Lopez, Chao Han, Dick E. de Vries, Stanley J. Marciniak, Chao Xu, Honghui Zhou, Rajesh Bandekar, Thomas A. Puchalski, Hugh M. Davis
Publikováno v:
Clinical Pharmacology in Drug Development. 3:328-334
Siltuximab, a monoclonal antibody (mAb) against interleukin (IL-6), is under development by Janssen Research & Development, LLC. During early clinical development, siltuximab was produced in a murine Sp2/0 myeloma cell line. The production cell line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26bf84404c19240239b00891c51344d6
https://doi.org/10.1002/cpdd.86
https://doi.org/10.1002/cpdd.86
Autor:
Zhenhua Xu, Craig Comisar, Hugh M. Davis, Bart Frederick, Joseph C. Marini, Bart van Hartingsveldt, Esther Bouman-Thio, Honghui Zhou
Publikováno v:
British Journal of Clinical Pharmacology. 72:270-281
AIMS To assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of sirukumab (CNTO 136) following intravenous (i.v.) infusion in healthy subjects.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79722fe4b12741d8b32158f6b9a4dc09
https://doi.org/10.1111/j.1365-2125.2011.03964.x
https://doi.org/10.1111/j.1365-2125.2011.03964.x
Autor:
Bruce E. Miller, Adam F. Cohen, Stephen Bai, John Getsy, Esther Bouman-Thio, Jennifer Yohrling, Hugh M. Davis, Kari L. Franson, Haishan Jang, Bart Frederick, Stanley J. Marciniak, Jacobus Burggraaf, Qun Jiao
Publikováno v:
The Journal of Clinical Pharmacology. 48:1197-1207
The erythropoietin mimetic antibody fusion protein CNTO 528 was developed as a novel antibody fusion protein by constructing an active hematopoietic peptide onto an IgG1-based scaffold. This resulted in a molecule with a long circulating half-life an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b4f497fcba0e648c1c05cac6c4693bb
https://doi.org/10.1177/0091270008322907
https://doi.org/10.1177/0091270008322907
Autor:
Gisela Torres, Eiko Toichi, Thomas S. McCormick, Kevin D. Cooper, Daniel E. Everitt, Mary Ann Mascelli, Bart Frederick, Catharine L. Kauffman, Timothy Chang, Charles Pendley, Nancy Aria, Alice B. Gottlieb
Publikováno v:
The Journal of Immunology. 177:4917-4926
Psoriasis is characterized by activation of T cells with a type 1 cytokine profile. IL-12 and IL-23 produced by APCs are essential for inducing Th1 effector cells. Promising clinical results of administration of an Ab specific for the p40 subunit of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc092042f2a0c88ff02ad4c20bff04ce
https://doi.org/10.4049/jimmunol.177.7.4917
https://doi.org/10.4049/jimmunol.177.7.4917
Autor:
Bart Frederick, Daniel E. Everitt, Mary Ann Mascelli, Yaowei Zhu, Charles Pendley, Alice B. Gottlieb, Martin A. Graham, Kevin D. Cooper, Nancy Aria, Thomas S. McCormick, Eiko Toichi, Catharine L. Kauffman
Publikováno v:
Journal of Investigative Dermatology. 123:1037-1044
The potential therapeutic activity of a human monoclonal antibody to the human interleukin-12 p40 subunit (anti-IL-12p40) has been established both in vitro and in vivo, warranting a first-in-human investigation in psoriasis. This phase I, first-in-h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::933691e893834476be2eaef7b31aa3c1
https://doi.org/10.1111/j.0022-202x.2004.23448.x
https://doi.org/10.1111/j.0022-202x.2004.23448.x
Autor:
John C. Pezzullo, Neal S. Kleiman, Bart Frederick, Darrell R. Abernethy, Jane E. Freedman, Mary Ann Mascelli
Publikováno v:
Clinical Pharmacology & Therapeutics. 71:186-195
Objectives Our objectives were to compare and contrast abciximab concentration-effect relationships in healthy volunteer participants with those in patients with coronary atherosclerosis undergoing elective coronary angioplasty. We also aimed to esta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6847d5583dce8c6790ad16cdd32edbbc
https://doi.org/10.1067/mcp.2002.121775
https://doi.org/10.1067/mcp.2002.121775
Autor:
Bart Frederick, Elliot S. Barnathan, Mary Ann Mascelli, Robert E. Jordan, John C. Pezzullo, Jane E. Freedman, Darrell R. Abernethy
Publikováno v:
American Heart Journal. 143:87-94
Objective The purpose of the study was to establish a rebolus regimen for abciximab that restores pharmacologic glycoprotein (GP) IIb/IIIa receptor blockade within a short time frame (up to 48 hours) after completion of an initial treatment. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f005a0a0a2580823e167b23e4dd0a748
https://doi.org/10.1067/mhj.2002.119769
https://doi.org/10.1067/mhj.2002.119769
Autor:
Zhenhua Xu, Honghui Zhou, Stanley J. Marciniak, Lilianne Kim, Yanli Zhuang, Bart Frederick, Hugh M. Davis
Publikováno v:
Clinical therapeutics. 37(2)
Purpose This Phase 1 pharmacokinetic (PK) comparability study in healthy subjects was performed to compare the PK properties and tolerability of single-dose golimumab 100 mg delivered subcutaneously by an autoinjector device or by a standard needle a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c9c1e9e88552583831b5bbd5ea70a78
https://pubmed.ncbi.nlm.nih.gov/25438720
https://pubmed.ncbi.nlm.nih.gov/25438720